Richard S. Finn, MD, Geffen School of Medicine
Advertisement
Articles by Richard S. Finn, MD, Geffen School of Medicine
Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.
HCC: Applying Recent Data Into Practice
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Emerging Therapies Under Investigation
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Combination Regimens for HCC Treatment
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Emerging Biomarkers in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Liver Function and Treatment Decisions
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Safety Profiles of Novel Therapies for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Sequencing of Novel Therapies in HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Regorafenib or Cabozantinib for Second-Line HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Selecting Second-Line Therapy for HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Second-Line Treatment for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Novel Combinations to Treat HCC
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Immunotherapy in Liver Cancer
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
HCC: Treating Patients With Atezolizumab/Bevacizumab
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
IO and VEGF Inhibition in Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
ByRichard S. Finn, MD, Geffen School of Medicine,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic,Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Reena Salgia, MD, Henry Ford Health System,Amit Singal, MD, UT Southwestern Medical Center
Advertisement
Latest Updated Articles
Emerging Biomarkers in Hepatocellular CarcinomaPublished: July 13th 2020 | Updated:
Screening Vs Diagnosis: Assessing Liver FunctionPublished: October 30th 2020 | Updated:
Immunotherapy Monotherapy in Later-Line SettingPublished: October 30th 2020 | Updated:
Regorafenib or Cabozantinib for Second-Line HCCPublished: July 13th 2020 | Updated:
HCC: Emerging Therapies Under InvestigationPublished: July 13th 2020 | Updated:
Hepatocellular Carcinoma: Diagnostic Work-UpPublished: July 13th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5